Boston Scientific Corporation (BSX) — closed signal from September 26, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 25, 2025 — -3.1% at the close.
Predicted vs. what happened
What happened
Reached 36% of the predicted growth at its peak, without hitting the target.
The thesis — published September 26, 2025
The stock has fallen more than usual and could rebound soon, though some trend signals still point down. The company leads in single-use scopes used for digestive care, and that market is expected to grow about 28% a year. A U.S. trade review on medical imports could make prices swing. Consider buying in steps over the next 0-3 months as the recent average price flattens and buying strength improves.
Primary drivers
- Price looks washed out, hinting at a near-term rebound if selling pressure eases.
- Strong position in single-use scopes, a fast-growing area of hospital tools.
- U.S. import review may create bigger-than-normal day-to-day price swings.
- Add more only after the recent average price steadies and starts to tilt up.
How it played out
BSX: rebound faded before the target
Lyra published BSX on 2025-09-26 at 99.21, with 18% expected growth. The thesis pointed to a washed-out price that could rebound if selling eased, strength in single-use scopes for digestive care, possible U.S. import-review volatility, and a plan to add only after the recent average price steadied.
Inside the window, BSX rose to 105.65 on 2025-11-13, a 6.5% peak gain. It stayed below the 117.07 target and never reached it. By 2025-12-25, it ended at 96.13. The thesis partially played out, then faded.
What happened during the window
On 2025-10-22, Investor's Business Daily reported that Boston Scientific posted adjusted earnings of $0.75 per share on $5.07 billion in revenue for the third quarter. The same report said Watchman sales grew 35% and electrophysiology sales rose 63%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.